PAR 2.38% 20.5¢ paradigm biopharmaceuticals limited..

Ann: Investor Presentation - $66m Capital Raise, page-76

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 4,420 Posts.
    lightbulb Created with Sketch. 6962
    Kiwinvestor, there have been at least a couple, the most prominent in my mind is the donkey study. There was one also performed on MPS rats which was pretty amazing.

    These excerpts from the Donkey study duly referenced below for your reading pleasure:


    "This study confirms the previous reports on repair of articular
    cartilage in the horses. Among these studies, it is generally accepted
    that articular cartilage has limited reparative powers".



    "These data clearly demonstrate the ability of PPS to stimulate the
    biosynthesis of components of the extracellular matrix accompanied by
    limiting their degradation by its anticatabolic effects".




    https://irp-cdn.multiscreensite.com/d048e3f1/files/uploaded/JT%20-%20Pentosan-polysulfate-as-a-disease-modifier.pdf



 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
20.5¢
Change
-0.005(2.38%)
Mkt cap ! $71.73M
Open High Low Value Volume
20.0¢ 21.0¢ 20.0¢ $152.8K 744.7K

Buyers (Bids)

No. Vol. Price($)
3 78174 20.5¢
 

Sellers (Offers)

Price($) Vol. No.
21.0¢ 84426 5
View Market Depth
Last trade - 16.10pm 01/11/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.